ASA dosing, risks and benefits

By  |  November 7, 2008 | 

We know that increasing the dose of ASA increases the risk of major and minor bleeding (abstract), but it is unclear if the efficacy also increases with increasing dose. This was a retrospective analysis of a larger study (BRAVO trial) which enrolled patients with a recent vascular event (MI, USA, TIA, or CVA) or dual bed vascular disease, and randomized them to an oral IIb/IIIa inhibitor or placebo. In this retrospective review, researchers evaluated the ASA dose (<162 or >162mg) in those 4590 patients that recieved a placebo in the inital trial. They found all cause mortality significantly lower in the higher dose ASA group at 1 year (2.9% in those <162mg and 1.6% in those >162mg, p=.003), and also found higher overall bleeding risk (but no significant difference in major bleeding). This suggests that ASA dose >162mg is more efficacious than <162mg in preventing death in those with a recent event or signficant vascular disease, at the expense of minor (but not major) bleeding (citation: Aronow DH et al; Am J Card 2008;102(10):1285)

One Comment

  1. Ajith Purush, MD November 20, 2008 at 5:05 pm - Reply

    Eliciting history of asthma or airway disease prior to giving aspirin is important. Also there is the question of aspirin insensitivity which was originally stated ti be as high as 30% but a new italian study puts it at 5%. comments.

Leave A Comment

About the Author: Danielle Scheurer

Danielle Scheurer
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.


Related Posts

By  | June 18, 2018 |  0
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis.  ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
By  | July 5, 2016 |  0
What comes to mind when you think of getting CME? I bet most of you would say sitting in an auditorium, whether that be during your local grand rounds or at our professional society meeting, like Hospital Medicine 16 in sunny San Diego this past March. Hanging out in the Twitterverse? Probably not so much… […]
By  | December 3, 2013 |  1
As a nurse practitioner in hospital medicine I have multiple opportunities to interact with all sorts of physician hospitalist colleagues, hospital medicine group leaders, quality officers etc.  Often their interactions with me take on a certain wary curiosity, like I am some exotic monkey or another creature that is unfamiliar to them.  If I am […]